Literature DB >> 18363739

Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency.

T Yasuno1, H Kaneoka, T Tokuyasu, J Aoki, S Yoshida, M Takayanagi, A Ohtake, M Kanazawa, A Ogawa, K Tojo, T Saito.   

Abstract

Carnitine palmitoyltransferase II (CPT II) deficiency is an inherited disorder involving beta-oxidation of long-chain fatty acids. CPT II deficiency is a wide-spectrum disorder that includes a lethal neonatal form, an infantile form, and an adult-onset form. However, the ethnic characteristics and the relationship between genotype and clinical manifestation are not well understood. We investigated three non-consanguineous Japanese patients with CPT II deficiency and examined cell lines from 4 unrelated patients and 50 healthy donors. The CPT 2 gene was typed by direct DNA sequencing of polymerase chain reaction-amplified gene products. Case 1 (infantile form) was heterozygous for a phenylalanine to tyrosine substitution at position 383 (p.F383Y) and a novel valine to leucine substitution at 605 (p.V605L). Cases 2, 4, and 5 (infantile form) and case 3 (adult-onset form) were heterozygous for a single mutation at F383Y. Case 6 (adult-onset form) was compound heterozygous at the CPT 2 locus, with deletion of cytosine and thymine at residue 408, resulting in a stop signal at 420 (p.Y408fsX420), and an arginine to cysteine substitution at position 631 (p.R631C). Case 7 (adult-onset form) was homozygous for the p.F383Y mutation. In conclusion, we identified p.F383Y mutations in six of seven patients with CPT II deficiency and two novel variants of the coding gene: p.Y408fsX420 and p.V605L. These mutations differ from those in Caucasian patients, who commonly harbor p.S113L, p.P50H, and p.Q413fsX449 mutations; therefore, our data and those of other Japanese groups suggest that the p.F383Y mutation is significant in Japanese patients with CPT II deficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18363739     DOI: 10.1111/j.1399-0004.2008.00986.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  11 in total

Review 1.  Carnitine palmitoyltransferase II deficiency with a focus on newborn screening.

Authors:  Go Tajima; Keiichi Hara; Miori Yuasa
Journal:  J Hum Genet       Date:  2018-12-04       Impact factor: 3.172

Review 2.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

3.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

Review 4.  Rhabdomyolysis caused by carnitine palmitoyltransferase 2 deficiency: A case report and systematic review of the literature.

Authors:  Nicholas Ivin; Valentina Della Torre; Francis Sanders; Matthew Youngman
Journal:  J Intensive Care Soc       Date:  2019-12-18

5.  Metabolic autopsy with next generation sequencing in sudden unexpected death in infancy: Postmortem diagnosis of fatty acid oxidation disorders.

Authors:  Takuma Yamamoto; Hiroyuki Mishima; Hajime Mizukami; Yuki Fukahori; Takahiro Umehara; Takehiko Murase; Masamune Kobayashi; Shinjiro Mori; Tomonori Nagai; Tatsushige Fukunaga; Seiji Yamaguchi; Koh-Ichiro Yoshiura; Kazuya Ikematsu
Journal:  Mol Genet Metab Rep       Date:  2015-10-02

6.  Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development.

Authors:  Ivan Shelihan; Elsa Rossignol; Jean-Claude Décarie; Jean-Paul Bonnefont; Michèle Brivet; Catherine Brunel-Guitton; Grant A Mitchell
Journal:  JIMD Rep       Date:  2021-09-29

7.  Cardiolipin Stabilizes and Increases Catalytic Efficiency of Carnitine Palmitoyltransferase II and Its Variants S113L, P50H, and Y479F.

Authors:  Beate Meinhardt; Leila Motlagh Scholle; Franziska Seifert; Martina Anwand; Markus Pietzsch; Stephan Zierz
Journal:  Int J Mol Sci       Date:  2021-05-02       Impact factor: 5.923

8.  A newborn case with carnitine palmitoyltransferase II deficiency initially judged as unaffected by acylcarnitine analysis soon after birth.

Authors:  Kenji Yamada; Ryosuke Bo; Hironori Kobayashi; Yuki Hasegawa; Mako Ago; Seiji Fukuda; Seiji Yamaguchi; Takeshi Taketani
Journal:  Mol Genet Metab Rep       Date:  2017-05-02

Review 9.  Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach.

Authors:  Pushpa Raj Joshi; Stephan Zierz
Journal:  Molecules       Date:  2020-04-13       Impact factor: 4.411

10.  Need for strict clinical management of patients with carnitine palmitoyltransferase II deficiency: Experience with two cases detected by expanded newborn screening.

Authors:  Ryosuke Bo; Ikuma Musha; Kenji Yamada; Hironori Kobayashi; Yuki Hasegawa; Hiroyuki Awano; Masato Arao; Toru Kikuchi; Takeshi Taketani; Akira Ohtake; Seiji Yamaguchi; Kazumoto Iijima
Journal:  Mol Genet Metab Rep       Date:  2020-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.